Yan Ming
SEC Form 4 history for the last 180 days across 1 company, 12 transactions and 1 filing.
Period: Last 180 days
Trade dates in this period: Aug 18, 2026 – Aug 18, 2026
Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.
Latest insider transactions
Form 4 filings from the last 180 days.| Company | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Tax withholdingForm 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction. | −$16.2kView disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | —View disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Tax withholdingForm 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction. | −$7.01kView disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | —View disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Tax withholdingForm 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction. | −$6.29kView disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | —View disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Tax withholdingForm 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction. | −$8.30kView disclosure → | |
CTKBCytek Biosciences, Inc. | Chief Technology OfficerCTO Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | —View disclosure → |
Latest Form 4 facts
Quick context from source filings
No latest transaction fact is available.
No open-market insider purchase is available.
No open-market insider sale is available.
Monthly open-market activity
Last 1 reported month · purchases and sales
No open-market purchases or sales in this history.
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Aug 2026 | 0 | 0 | $0 | $0 | $0 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Counts cover all available history, including outside the summary period
Open-market buy performance
90-day forward return on this insider's open-market purchases
A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
8 observations · Aug 18, 2026 – Aug 18, 2026. Window ends at the latest available report, not today.
View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Aug 18, 2026 | 4,804,051 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 4,802,273 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 4,807,798 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 4,806,452 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 4,812,614 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 4,811,113 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 4,825,333 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 4,821,870 | Aug 20, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Yan Ming Insider Activity FAQ
SEC Form 4 context
Who is Yan Ming?
Yan Ming is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001874041.
Which companies has Yan Ming reported transactions for?
Cytek Biosciences, Inc.
When was Yan Ming's latest insider buy?
No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.
When was Yan Ming's latest insider sale?
No open-market insider sale is recorded in the last 180 days. Earlier filings are outside the visible history.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.